Aleksandr Lazaryan

26PUBLICATIONS
188CO-AUTHORS
Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)HaematologyPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (26)

|Jul 21, 2026
Chronic graft-versus-host disease after PTCy-based prophylaxis vs non-PTCy prophylaxis.

|Jul 17, 2026
A novel severe toxicity-free, and progression-free survival endpoint predicts outcomes after CD19 chimeric antigen receptor-T cell therapy in large B-cell lymphoma.

|Jun 20, 2026
Expanded antigen-specific donor regulatory T cells for GVHD prevention.

|Apr 15, 2026
Haploidentical versus matched unrelated donor transplantation with post-transplant cyclophosphamide: a platform-dependent machine learning analysis of donor age.

|Aug 28, 2025
Efficacy and safety of belumosudil as compared with best available therapy for the treatment of cGVHD in the United States.

Kevin Hall, Aleksandr Lazaryan, Mark van der Laan

|Apr 16, 2025
Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B-cell Lymphoma.

Khushali Jhaveri, Ram Thapa, Dalia Ercan

Pageof 5

Frequent Collaborators

13 joint publications

Taiga Nishihori

10 joint publications

Michael Jain

9 joint publications

Nelli Bejanyan

7 joint publications

Marco L Davila